Editors' Note: This article covers a stock trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.
Colorectal cancer is the third most prevalent cancer in the US, with roughly one in 20 people diagnosed with the disease. While screening methods, such as the colonoscopy and fecal tests (FOBT/FIT) are used regularly, low patient compliance means that many people continue to be diagnosed later than ideal. However two companies, Exact Sciences (NASDAQ:EXAS) and VolitionRx (NYSEMKT:VNRX) are developing very different tests which each claim to pick up cancer earlier, using more sophisticated DNA-based analysis than is currently available.
Exact Sciences was...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|